African Regional IP Organization (ARIPO): These 5 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in African Regional IP Organization (ARIPO)
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: African Regional IP Organization (ARIPO): These 5 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
Tradename | Ingredient | Estimated Entry Opportunity Date |
---|---|---|
ESBRIET | pirfenidone | 2025-09-22 |
OLYSIO | simeprevir sodium | 2025-07-29 |
INCRUSE ELLIPTA | umeclidinium bromide | 2024-04-27 |
>Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: African Regional IP Organization (ARIPO): These 5 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,655
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,406
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-nine patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,213
INCRUSE ELLIPTA is a drug marketed by
This drug has one hundred and seven patent family members in thirty-seven countries. There has been litigation on patents covering INCRUSE ELLIPTA
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can BYVALSON (nebivolol hydrochloride; valsartan) generic drug versions launch?
Generic name: nebivolol hydrochloride; valsartan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 04, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,815
BYVALSON is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-seven patent family members in fifteen countries. There has been litigation on patents covering BYVALSON
See drug price trends for BYVALSON.
The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. Additional details are available on the nebivolol hydrochloride; valsartan profile page.
When can BYVALSON (nebivolol hydrochloride; valsartan) generic drug versions launch?
Generic name: nebivolol hydrochloride; valsartan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 04, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,896
BYVALSON is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-seven patent family members in fifteen countries. There has been litigation on patents covering BYVALSON
See drug price trends for BYVALSON.
The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. Additional details are available on the nebivolol hydrochloride; valsartan profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 1,907
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 06, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,204
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-two patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 1,956
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can ZTALMY (ganaxolone) generic drug versions launch?
Generic name: ganaxolone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2025
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 3,071
ZTALMY is a drug marketed by Marinus. There are eight patents protecting this drug.
This drug has forty-three patent family members in fifteen countries.
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.